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Abstract 
Background and Objective: Pulpitis is mainly caused by an opportunistic infection of 
the pulp space with commensal oral microorganisms. Depending on the state of inflammation, 
different treatment regimes are currently advocated. Predictable vital pulp therapy depends on 
accurate determination of the pulpal status that will allow repair to occur. The role of several 
players of the host response in pulpitis is well documented: cytokines, proteases, inflammatory 
mediators, growth factors, antimicrobial peptides and others contribute to pulpal defense 
mechanisms; these factors may serve as biomarkers that indicate the status of the pulp. 
Therefore, the aim of this systematic review was to evaluate the presence of biomarkers in 
pulpitis. 
Methods: The electronic databases of MEDLINE, EMBASE, Scopus and other sources were 
searched for English and non-English articles published through February 2015. Two 
independent reviewers extracted information regarding study design, tissue or analyte used, 
outcome measures, results and conclusions for each article. The quality of the included studies 
was assessed using a modification of the Newcastle-Ottawa-Scale. 
Results and Conclusions: From the initial 847 publications evaluated, a total of 57 
articles were included in this review. In general, irreversible pulpitis was associated with 
different expression of various biomarkers compared to normal controls. These biomarkers were 
significantly expressed not only in pulp tissue, but also in gingival crevicular fluid that can be 
collected non-invasively, and in dentin fluid that can be analyzed without extirpating the entire 
pulpal tissue. Such data may then be used to accurately differentiate diseased from healthy pulp 
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tissue. The interplay of pulpal biomarkers and their potential use for a more accurate and 
biologically based diagnostic tool in endodontics is envisaged.  
 
Introduction 
The dental pulp is equipped to express numerous mediators of inflammation, which can combat 
irritating factors [1-4]. Its mechanistic response begins with vascular changes mediated by Toll-
like receptors (TLR) 4/2-positive cells and includes release of measurable inflammatory 
mediators such as IL-8, IL-6, IL-1 and others [4-7]. Under normal physiologic conditions (left in 
Fig 1), the vasculature consists of central vessels that branch out into a plexus towards the 
periphery and specifically the pulp horns. An important difference from soft tissue-enclosed 
portions of the body is that dental hard tissues enclose the pulp creating a low compliance 
environment. Dental blood vessels are mainly under control by local metabolites and less by 
sympathetic innervation. The main cellular components of the pulp are peripherally located 
odontoblasts and stromal fibroblasts. There are also undifferentiated mesenchymal cells found 
mainly in the paravascular niche and immune cells (Fig 1). In health, neutrophils predominate 
but dendritic cells and occasional macrophages are also found.  
 
Fig 1. Schematic illustration of a tooth with a healthy pulp (left panel) and an inflamed 
pulp (right panel) subjacent to a caries lesion. Involved factors and biological effectors are 
indicated for both pulpal conditions. 
 
Inflammation of the dental pulp (pulpitis) has been viewed as a tightly regulated sequence of 
vascular and cellular events mediated by molecular factors [8]. Pulpitis is typically caused by an 
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opportunistic infection of the pulp space by commensal oral microorganisms [9]. The most 
common route of entry for the microorganisms is dental caries. Other potential pathways for 
pulpal microbial infection include trauma, dentinal cracks, exposed dentinal tubules or the main 
apical foramen [10]. Cells in human dental pulp that express TLR contribute trigger immune 
responses to microorganisms and their by-products [2-4]. This group includes odontoblasts [11], 
endothelial cells [12] as well as macrophages and dendritic cells [13]. Some of these cells may 
form mechanical barriers (i.e. odontoblasts), detect and transmit sensations (nerve fibers) or 
differentiate (i.e. dental pulp stem cells) to limit infection, signal injury and promote repair, 
respectively.  
Based on the patients’ signs, symptoms, and examination, four clinical pulpal conditions are 
described: normal, reversibly inflamed, irreversibly inflamed or necrotic [14]. Histology 
represents the gold standard to determine the inflammatory state of pulp tissue [15, 16]; however, 
it is generally agreed that histologic and clinical classification of pulpal diagnosis still needs to 
be improved and refined. Normal and necrotic pulps have straightforward histological 
presentation. The conundrum lies in differentiating reversible and irreversible pulpitis. Based on 
histological reports, reversible pulpitis is characterized by the absence of bacteria and by 
localized coagulation and liquefaction necrosis immediately surrounding the irritant, whereas 
irreversible pulpitis is characterized by the presence of the bacteria or their by-products in the 
dental pulp and by preponderance of acute inflammatory cells predominantly neutrophils in the 
tissue beneath the lesion suggesting chemotactic activity. Lysosomal enzymes discharged by 
neutrophils result in widespread tissue damage and suppuration [16-18]. Acute pulpitis 
(reversible, and irreversible) can be an extremely painful condition and is believed to be one of 
the main causes for patients to seek emergency dental treatment during or after office hours [19, 
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20]. The main clinical difference between reversible and irreversible pulpitis is in the pulp’s 
response to thermal stimulus. Reversible pulpitis presents an exaggerated yet non-lingering 
response to cold stimulus. Irreversible pulpitis on the other hand is characterized by constant, 
spontaneous pain with exaggerated and lingering response to cold stimulus. However, forty 
percent of teeth with irreversible pulpitis can be painless [21]. In reversible pulpitis, the pulp is 
expected to recover after removal of the causative stimulus. In contrast, if the pulp is irreversibly 
inflamed, healing is not expected and pulpectomy (i.e., full removal of the dental pulp) is 
indicated.  
The succession of signaling events resulting from dental pulp stimulation by microorganisms to 
the release of an array of immune mediators that in turn may cause pulpal or odontogenic pain, 
pulpitis, or in advanced stages, pulpal necrosis and finally apical periodontitis have been well 
described in the past [4-7]. Detailed discussion of these mechanisms is beyond the scope of this 
article. 
Currently, diagnostic procedures that aim to assess pulpal inflammation involve case history, as 
well as clinical and radiographic examination. Clinical examination includes different procedures 
such as inspection, pulp sensitivity to thermal or electric stimuli, and pain on palpation or 
percussion. These procedures apparently did not change much in the last century [22]. However, 
the validity of the currently employed clinical tests to determine the actual or histopathological 
status of the pulp remains controversial [15]. A recently performed literature review summarized 
the available information on the diagnostic accuracy of signs/symptoms and current tests used to 
determine the condition of the pulp [23]. These authors concluded that the overall evidence was 
insufficient to support the accuracy of such test, even if the tests are combined. Hence, the 
current diagnostic procedures do not reliably identify the inflammatory status of the pulp. This is 
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particularly unfortunate since decision making in this field, for example differentiation between 
vital pulp therapy and root canal treatment, critically depends on an accurate pulpal diagnosis. 
According to the National Library of Medicines, the medical subject heading term (MeSH term) 
definition for a biological marker is a measurable and quantifiable biological parameter that 
serves as an indicator for health- and physiology-related assessments. Molecules expressed in the 
cascade of tissue inflammation may serve as (diagnostic) biomarkers for the presence of 
inflammation. Some research suggests that the dental pulp is not an isolated entity in an encased, 
solid environment but a reactive tissue that extends its biological products into the outside 
environment [24, 25]. In fact, studies have shown that pulpal events can be reflected through 
measurable levels of protein markers that correlated with pulpal symptoms in pulpal blood [26], 
dentinal fluid [27], periapical fluid [28], and gingival crevicular fluid (GCF; [1, 29]).  
In the field of periodontology, biomarkers in oral fluids/saliva or gingival crevicular fluid are 
used to detect the occurrence and progression of periodontitis [30, 31]. For example, matrix 
metalloproteinases (MMPs) such as MMP-8 and -9 have been shown to be central biomarkers of 
soft tissue breakdown in periodontal pockets [32]. Periodontal and pulpal inflammation shares 
certain features: initially, both exhibit soft-tissue inflammation caused by microbial infection. At 
a later stage, these pathologic processes culminate in bone resorption (vertical bone-loss or apical 
periodontitis, respectively). It is therefore possible that both pathoses may express the same 
biomarkers. In this regard, MMPs were shown to be potential biomarker for both pulpal [33] and 
periodontal disease [32]. However, the application of molecular diagnostics in pulpal disease is 
as yet not used for clinical decision-making [34]. 
Previous studies have investigated the molecular regulatory pathways of pulpal inflammation 
employing explanted cell cultures in vitro [35-37]. However, the extrapolation of such results to 
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the clinical situation is difficult, perhaps due to the reductionist nature of such experiments. In 
vivo, the presence of other cellular players (e.g. immune cells), inhibitory proteins (e.g. protease 
inhibitors) and other molecules that modify the inflammatory response may present a completely 
different inflammatory response and consequently, a different clinical outcome compared with 
what may be suggested by in vitro experimental results. Studies reporting clinical samples for the 
presence of potential biomarkers for pulpal inflammation are still on the rise. The clinical 
importance of identifying these biomarkers that can be used to diagnose or to stage pulpal 
inflammation warrants not only additional studies but also a critical or systematic review and 
analysis of published reports. Therefore, the aim of this paper is to systematically review the 
currently available information on biomarkers that were identified from pulp tissues diagnosed as 
normal or inflamed. 
 
Systematic review 
Eligibility Criteria and Literature Search 
This systematic review was prepared in accordance with PRISMA (S1 Table) [38]. Studies were 
eligible for inclusion to the review that clinically and/ or histologically differentiate between a 
healthy and a irreversibly inflamed pulp in permanent human teeth, and analyzed interstitial/ 
dentinal liquor, gingival crevicular fluid, pulpal tissue, dentin fluid or apical blood for the 
presence of a biological marker. A biological marker is defined as measurable and quantifiable 
biological molecule that theoretically can be present in those substrates and might serve as an 
indicator for a healthy or diseased pulp (adapted from MeSH Unique ID: D015415). An 
electronic search strategy with combined keywords and indexing vocabulary (MeSH terms) was 
conducted in the Medline database of the US National Library of Medicine employing the 
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OvidSP interface. We used the following search terms and other subject headings: ‘pulpitis’, 
‘acute pulpitis’, ‘irreversible pulpitis’, ‘painful pulpitis’, ‘biological markers’, ‘inflammation 
mediators’, ‘dentinal fluid’, and ‘gingival crevicular fluid’. S2 Table lists the detailed search 
strategy performed in Medline. The same electronic search strategy was used in Biosis (OvidSP), 
the Cochrane library (Wiley), Embase (http://www.embase.com) and the Web of Science 
(Thomson Reuters). The last date entered was February 19, 2015. No language restrictions were 
imposed and all articles were included from the inception of the respective database (S3 Table). 
To ensure the completeness of the search, one reviewer (DRK) conducted a thorough search of 
the bibliographies of all included studies.  
 
Study Selection and Quality Assessment 
The search and selection process is summarized in Fig 2 [38]. A pool of 1733 records was 
initially identified using the electronic search strategy and other sources. After removal of 
duplicates, 851 records remained. Two reviewers (DKR and JCG) independently screened the 
titles and abstracts of the references collected. Communications not related to the topic were 
discarded (n=695). Communications deemed appropriate by one of the reviewers were assigned 
for full text evaluation. One hundred and fifty-six records were identified using this approach 
and reviewed as full texts. Articles were collected and evaluated independently by both 
reviewers. Non-English abstracts or manuscripts were translated with the help of translators. 
Further articles (n=99) were excluded for one of the following reasons: i) studies not on human 
teeth, ii) cell culture study only, iii) no potential biomarker was investigated or the study was off 
topic, iv) no clear distinction between reversible, irreversible or necrotic pulp, v) studies rather 
on histologic features or presence of cells, bacteria or viruses than on quantification of a 
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biomarker, vi) review articles, editorials, comments, abstract only or case reports (S4 Table). In 
case of disagreement consensus was achieved through discussion by third party arbitration 
(OAP). Articles where no exclusion criteria applied were included to the review. There was 
94.2% agreement prior to arbitration between both reviewers and finally 57 publications were 
included to the review. The included articles were written in English (n=54) or Chinese (n=3) 
language. 
 
Fig 2. PRISMA flowchart depicting the systematic selection and exclusion of articles 
related to the topic. A detailed description of the excluded articles with the respective reasons 
for exclusion is presented in the running text and S4 Table.  
 
Quality Assessment 
The quality of the included studies was assessed using a modification of the Newcastle-Ottawa-
Scale (NOS; [39, 40]). The NOS rates the 3 study domains ‘selection’, ‘comparability’ and 
‘outcome’. Each positive rating was awarded with a star. The parameters recorded for ‘selection’ 
were: selection of the cohort (gender and age distribution reported) and condition of the cohort 
(general health and medication reported). The parameters recorded for ‘comparability’ were: 
diagnostics of cases and controls (anamnesis, clinical and radiological inspection described in 
sufficient detail), histological confirmation of the diagnosis performed (yes/no), quality of the 
controls (control sample from the same patient as the case sample) and the ratio of the group size 
(cases:controls ≥ 1:2). The parameters recorded for ‘outcome’ were: reported blinding to the 
case/control status (yes/no) and that the same tests were performed with the cases and control 
samples (yes/no). Consequently two stars could be awarded for ‘selection’, four stars for 
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‘comparability’ and two stars for ‘outcome’. A value of ‘0’ represents the lowest study quality 
and ‘8’ the highest possible quality rating of the modified NOS. 
 
Data Extraction and Statistical Analysis 
Quantitative data were collected from all studies included to the review. An electronic protocol 
for data extraction was defined and piloted on several manuscripts before final completion. 
Relevant information regarding reference name, publication date, substrate analyzed for the 
presence of a biological marker, how was the substrate collected, number of specimens in 
experimental group and control group, was the substrate pooled before analysis (yes/no), name 
of the biological marker under investigation, what type of molecule is the biological marker, 
what general function serves the biological marker, what was the molecular expression level of 
the biological marker, which analyte was evaluated for the presence of the biological marker, 
which method was used for analysis, and were statistically significant differences between 
specimens of the irreversible pulpitis group compared to the control group (healthy pulp) 
reported (yes/no), were collected. The synthesis of the data is presented in a descriptive manner. 
Moreover, descriptive statistics were applied when deemed appropriate (JMP 10.0.0, SAS 
Institute, Cary, N.C., USA). 
 
Results 
Study Characteristics and Quality Assessment 
The studies excluded during full text evaluation (N=99; Fig 2) are presented in S4 Table. The 
studies included in the review are listed in Tables 1 and 2. Due to the heterogeneous nature of the 
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studies it was not possible to perform meta-analysis on their outcome. The quality ratings of the 
included studies according to the modified NOS are presented, along with the full reference, in 
S5 Table. The average quality score was 3.9 ± 1.1 (mean ± SD). Figure 3 provides an overview 
on the total ratings for the respective parameters for the study domains selection, comparability 
and outcome. Weaknesses were noticed for the parameters selection of the cohort, quality of the 
controls and reported blinding to the case/control status. 
 
Fig 3. Bar chart showing the quality ratings of the included studies based on a modified 
Newcastle-Ottawa-Scale. 
 
Tissues Studied 
Eighty-eight percent of the studies included (50/57; Table 1) analyzed pulp tissue for the 
presence of a biomarker either collected via pulpectomy (N=5), tooth extraction and fracturing 
(N=25), or a combination of both (N=20). Twelve percent (7/57; Table 2) of the studies included 
analyzed substrates other than pulp tissue: pulpal blood (N=2), peripheral blood serum (N=1), 
GCF (N=1), dentinal fluid (N=1), or extracellular pulpal fluid (N=2). Pulpal blood, GCF and 
dentinal fluid were collected using absorbable membranes, blood serum via peripheral blood 
collection and extracellular pulpal fluid by inserting microdialysis membranes into vital pulp 
tissue [41, 42]. Eighty-two percent of the studies analyzing pulp tissue (41/50) used tissue 
collected from extracted healthy, non-carious permanent, or wisdom teeth as their control. 
Fourteen percent (7/50) used healthy pulp tissue collected via pulpectomy because of elected 
root canal treatment for prosthetic reasons as their control. One study used tissues from 
extraction and pulpectomy as control [43], another one did not state precisely how they collected 
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control tissue [2]. Of the 7 studies evaluating substrates other than pulp tissue, two sampled 
blood [44, 45], and another one extracellular fluid [41] from healthy teeth that were assessed but 
subsequently planed for extraction because of prosthetic or orthodontic reasons as control. One 
study sampled venous (peripheral) blood during pulp inflammation and used a consecutive 
peripheral blood sample after treatment as control [46]. One further study sampled GCF from 
healthy contralateral or adjacent teeth as control [1], and another one collected dentinal fluid 
from non-symptomatic teeth scheduled for replacement of a filling as control [33]. The substrate 
in one study was pooled before performing the confirmatory test [47]. 
 
Confirmatory Tests 
Analytical methods used for the assessment of pulp tissue included reverse transcription 
polymerase chain reaction, multiplex assay, microarray, western blot, radioimmunoassay, 
immunohistochemistry, enzyme-linked immunosorbent assay, zymography, flow cytometry, 
limulus amoebocyte assay and specific enzyme assays (Table 1). Pulpal inflammation was 
confirmed by histology in 42% (21/50; Tables 1 and S5) of these studies. Substrates other than 
pulp tissue were analyzed using radioimmunoassay, enzyme-linked immunosorbent assay, 
specific serum, or enzyme assays (Table 2). Histology was not used to confirm pulpal diagnosis 
in those studies. Seventy-four percent of the studies evaluating pulp tissue (37/50) analyzed 
actual protein expression or protein activity, whereas 16% (8/50) analyzed the pulp tissue on the 
DNA level. Five studies (10%) analyzed the pulp tissue substrates at both levels (Table 1). All 
studies evaluating other substrates than pulp tissue evaluated protein expression or protein 
activity (Table 2). 
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Markers Studied 
Pulp tissue was assessed for a total of 89 biological markers. Statistical significant differences 
between an irreversible inflamed and a healthy pulp could be detected for 64 biological markers 
(71.9%) by at least one study. Nineteen biological markers showed no statistically significant 
differences between inflammation and health, whereas 6 biological markers were not evaluated 
employing statistical tests (Table 1). Substrate other than pulp tissue was evaluated for 16 
biological markers. For twelve biological marker (75%) statistical significant differences 
between irreversible inflammation and health could be detect by at least one study. 
 
Table 1. Studies assessing pulp tissue for the presence of biomarkers associated with pulpal 
condition. 
 
Reference  
n per group 
(irreversibly 
inflamed/ 
non-
inflamed) Biomarker Function Target Analyte Method 
Significant 
difference 
between 
groups  
Cytokines 
Zehnder et al. 
2003 [48] 
11/13 IL-1α Regulates immune and 
inflammatory reactions; 
stimulates bone 
resorption 
mRNA PTS RT-PCR n 
Abd-Elmeguid et 
al. 2013* [49] 
12/30   Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 IL-1rα Acute phase protein that 
increases neutrophil 
presence of  
Protein PTS Multiplex 
assay 
y 
Zehnder et al. 
2003 [48] 
11/13 IL-1β Regulates immune and 
inflammatory reactions; 
stimulates bone 
resorption 
mRNA PTS RT-PCR n 
Paris et al. 2009 
[50] 
10/7   mRNA PTS RT-PCR  y 
Silva et al. 2009* 
[51] 
5/5   Protein PTS ELISA n 
Abd-Elmeguid et 
al. 2013* [49] 
12/30   Protein PTS Multiplex 
assay 
y 
Rauschenberger 
et al. 1997* [52] 
15/17 IL-2 Regulates activities of 
leukocytes 
Protein PTS ELISA y 
Anderson et al. 
2002 [53] 
32/24   Protein PTS ELISA n 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 IL-4  Key regulator in humoral 
and adaptive immunity; 
stimulates activated B 
Protein PTS Multiplex 
assay 
y 
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cells, T-cell proliferation, 
and the differentiation of 
B-cells into plasma cells 
Zehnder et al. 
2003 [48] 
11/13 IL-6 Regulator of T- and B-
cell growth, acute phase 
protein production 
 
mRNA PTS RT-PCR y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30   Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 IL-7  Stimulates proliferation 
and maturation of B and 
T cells  
Protein PTS Multiplex 
assay 
y 
Huang et al. 
1999* [54] 
14/15 IL-8 Recruitment and 
activation of neutrophils  
Protein PTS ELISA y 
Zehnder et al. 
2003 [48] 
11/13   mRNA PTS RT-PCR y 
Silva et al. 2009* 
[51] * 
5/5   Protein PTS ELISA n 
Abd-Elmeguid et 
al. 2013* [49] 
12/30   Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 IL-12p40 Subunit of IL-12; acts on 
T- and natural killer cells 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 IL-13  Mediator of allergic 
inflammation and 
disease 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 IL-15  Induces proliferation of 
natural killer cells 
Protein PTS Multiplex 
assay 
n 
Zehnder et al. 
2003 [48] 
11/13 IL-18 Pro-inflammatory 
cytokine involved in cell 
mediated immunity 
mRNA PTS RT-PCR y 
Pezelj-Ribaric et 
al. 2002 [55] 
19/18 TNF-α Delays neutrophil 
apoptosis 
Protein PTS ELISA y 
Kokkas et al. 
2007 [43] 
6/6   mRNA PTS RT-PCR y 
Keller et al. 2009 
[56] 
5/5   mRNA PTS RT-PCR y 
Paris et al. 2009 
[50] 
10/7   mRNA PTS RT-PCR  y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30   Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 TNF-β Mediates a large variety 
of inflammatory, 
immunostimulatory, and 
antiviral responses 
Protein PTS Multiplex 
assay 
n 
Li et al. 2011* 
[57] 
4/4 MIP-1α Mediate immune 
responses towards 
infection and 
inflammation; activation 
of granulocytes 
mRNA PTS RT-PCR y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30   Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 MIP-1β  Mediate immune 
responses towards 
infection and 
inflammation; activation 
of granulocytes 
Protein PTS Multiplex 
assay 
y 
Nakanishi et al. 
2005* [58] 
8/5 MIP-3α  Chemoattractant for 
lymphocytes and 
neutrophils  
Protein FPT IHC n/a  
Nakanishi et al. 
2005* [58] 
8/5 CCR6  MIP-3α Receptor on 
memory T-cells, 
dendritic cells and Th17 
cells 
Protein FPT IHC n/a 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 TGF-α  Induces epithelial 
development and wound 
healing 
Protein PTS Multiplex 
assay 
y 
Piattelli et al. 
2004* [59] 
20/23 TGF-β1 Modulates pro-
inflammatory cytokine 
production, inhibits 
mitogenic effects of IL-2 
Protein FPT IHC y 
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on T and B lymphocytes, 
blocks activity of other 
immunocompetent cells 
Adachi et al. 
2007* [60] 
9/4 CXCL10 Chemoattractant for 
monocytes/macrophage
s, T cells, NK cells, and 
dendritic cells 
Protein PTS RT-PCR y 
 5/4   Protein FPT IHC n/a 
Jiang et al. 
2008* [61] 
6/5 SDF-1 Chemotactic for 
lymphocytes 
mRNA PTS RT-PCR y 
 4/4   Protein FPT IHC n/a 
Huang et al. 
2009* [62] 
15/15 Oncostatin 
M 
Involved in 
hematopoiesis, tissue 
remodelling processes 
and inflammation 
mRNA PTS RT-PCR y 
    Protein FPT IHC y 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 GM-CSF Stimulates production of 
granulocytes and 
monocytes 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 GRO Neutrophil 
chemoattractant. 
Involved in 
angiogenesis, 
inflammation, wound 
healing and 
tumorigenesis 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 MCP-1  Chemoattractant for 
monocytes, recruits 
memory T cells, and 
dendritic cells to the 
sites of inflammation 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 MCP-3  Chemoattractant for 
monocytes; regulates 
macrophage function 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 MDC  Chemotactic for 
monocytes, dendritic 
cells and natural killer 
cells 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 INF-α  Antiviral agents, 
modulate functions of 
the immune system 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 G-CSF  Stimulates proliferation 
and differentiation of 
granulocytes 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 Eotaxin-1  Recruits eosinophils by 
inducing their 
chemotaxis 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 flt3ligand  Stimulates proliferation 
and differentiation of 
various blood cell 
progenitors 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 Fractalkin
e 
Chemoattractant for T 
cells and monocytes; 
promotes strong 
adhesion of leukocytes 
to activated endothelial 
cells 
Protein PTS Multiplex 
assay 
y 
Abd-Elmeguid et 
al. 2013* [49] 
 CD40L Co-stimulatory molecule 
for T cells; promotes B 
cell maturation and 
function 
Protein PTS Multiplex 
assay 
n 
Abd-Elmeguid et 
al. 2013* [49] 
 sIL-2rα  Receptor that mediates 
IL-2 activities; increased 
levels biological fluids 
correlate with increased 
immune system 
activation 
Protein PTS Multiplex 
assay 
n 
Abd-Elmeguid et  IP-10  Chemoattractant for Protein PTS Multiplex n 
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al. 2013* [49] monocytes/macrophage
s, T cells, NK cells, and 
dendritic cells 
assay 
Abd-Elmeguid et 
al. 2013* [49] 
 PDGF-AA  Receptor that regulates 
cell proliferation, cellular 
differentiation, cell 
growth and development 
Protein PTS Multiplex 
assay 
n 
Abd-Elmeguid et 
al. 2013* [49] 
 PDGF-
AB/BB 
Receptor that regulates 
cell proliferation, cellular 
differentiation, cell 
growth and development 
Protein PTS Multiplex 
assay 
n 
Abd-Elmeguid et 
al. 2013* [49] 
 RANTES Chemoattractant for 
leukocytes to 
inflammatory sites; 
proliferation and 
activation of natural-
killer cells 
Protein PTS Multiplex 
assay 
n 
Abd-Elmeguid et 
al. 2013* [49] 
 Osteocalci
n 
Regulation of bone 
mineralization 
Protein PTS Multiplex 
assay 
y 
    Protein FPT IHC n/a 
Proteases and other enzymes 
Gusman et al. 
2002 [63] 
17/18 MMP-1 Regulator of connective 
tissue remodeling 
Protein PTS ELISA Not detected 
Gusman et al. 
2002 [63] 
17/18 MMP-2 Hydrolysis of 
intercellular matrix 
Protein PTS ELISA y 
Accorsi-
Mendonca et al. 
2013 [64] 
 
10/10   Protein PTS Zymography  y 
Accorsi-
Mendonca et al. 
2013 [64] 
 
10/10 pro-MMP-
2 
Pro-form of MMP-2 Protein PTS Zymography  n 
Gusman et al. 
2002 [63] 
17/18 MMP-3 Hydrolysis of 
intercellular matrix 
Protein PTS ELISA y 
Tsai et al. 2005* 
[65] 
14/14   mRNA PTS RT-PCR y 
    Protein FPT IHC y 
Gusman et al. 
2002 [63] 
17/18 MMP-9 Hydrolysis of 
intercellular matrix; 
regulatory factor for 
neutrophil migration 
across basement 
membrane 
Protein PTS ELISA y 
Suwanchai et al. 
2012 [66] 
7/18   Protein PTS Western Blot y 
Accorsi-
Mendonca et al. 
2013 [64] 
 
10/10   Protein PTS Zymography n/a 
Huang et al. 
2005* [67] 
 
17/13 
 
t-PA Involved in soft-tissue 
breakdown; catalyzes 
the conversion of 
plasminogen to plasmin 
mRNA PTS RT-PCR y 
    Protein FPT IHC n/a 
Huang et al. 
2007* [68] 
22/9   Protein PTS Zymography y 
 22/9   Protein PTS ELISA y 
Ge et al. 1996 
[69] 
 
12/9 SOD Antioxidant Protein 
activity 
PTS Enzyme 
assay 
y 
Tulunoglu et al. 
1998 [70] 
 
10/7   Protein 
activity 
PTS Enzyme 
assay 
n 
Bodor et al. 16/10 Cu, ZN- Protection against mRNA PTS RT-PCR y 
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2007 [71] 
 
SOD reactive oxygen species  
Varvara et al. 
2005 [72]  
13/12   Protein 
activity 
PTS Enzyme 
assay 
y 
Bodor et al. 
2007 [71] 
 
16/10 Mn-SOD Protection against 
reactive oxygen species 
mRNA PTS RT-PCR y 
Ge et al. 1996 
[69] 
 
12/9 MDA Oxidative stressor Protein 
activity 
PTS Enzyme 
assay 
y 
Cootauco et al. 
1993* [73] 
 
5/8 Elastase Cleavage of elastin, 
collagen, proteoglycans 
Protein FPT IHC y 
  Cathepsin-
G 
Proteolysis Protein FPT IHC y 
Spoto, Fioroni, 
Rubini, Tripodi, 
Di Stilio, et al. 
2001 [74]  
 
10/10 Alkaline 
phosphata
se 
Hydrolysis of phosphate 
ester-bonds 
Protein 
activity 
PTS Enzyme 
assay 
n 
Spoto, Fioroni, 
Rubini, Tripodi, 
Perinetti, et al. 
2001 [75]  
 
20/20 Aspartate 
Aminotran
sferase 
Catalyzes transfer of 
aminotransferase amino 
group of aspartate to α-
ketoglutarat 
Protein 
activity 
PTS Enzyme 
assay 
n 
Esposito, 
Varvara, Caputi, 
et al. 2003 [76]  
 
15/18 Catalase Catalyzes the 
breakdown of hydrogen 
peroxide 
Protein 
activity 
PTS Enzyme 
assay 
y 
Esposito, 
Varvara, 
Murmura, et al. 
2003 [77]  
12/11   Protein 
activity 
PTS Enzyme 
assay 
y 
da Silva et al. 
2008* [78] 
 
6/6 NADPH-
diaphoras
e 
Detoxification to produce 
ROS 
Protein FPT IHC y 
Di Nardo Di 
Maio et al. 2004* 
[79] 
 
10/10 eNOS Nitric oxide synthase mRNA 
 
PTS RT-PCR y 
    Protein PTS Western blot y 
    Protein FPT IHC y 
 10/10 iNOS Nitric oxide synthase mRNA PTS RT-PCR y 
    Protein PTS Western blot y 
    Protein FPT IHC y 
Spoto, Ferrante, 
et al. 2004 [80]  
 
6/12 cGMP 
PDE 
Hydrolysis of cyclic 
nucleotide 
Protein 
activity 
PTS Enzyme 
assay 
y 
Spoto, Menna, 
et al. 2004 [81] 
 
6/12 cAMP 
PDE 
Hydrolysis of cyclic 
nucleotide 
Protein 
activity 
PTS Enzyme 
assay 
y 
Accorsi-
Mendonca et al. 
2013 [64] 
 
10/10 TIMP-2 Inhibits MMP-2 Protein PTS ELISA y 
  MPO Generation of reactive 
oxygen species 
Protein 
activity 
PTS Enzyme 
assay 
y 
Inflammatory mediators 
Bolanos and 
Seltzer 1981 
[82] 
17/7 cAMP Activation of protein 
kinases 
Protein PTS RIA n 
  cGMP Activation of protein 
kinases 
Protein PTS RIA n 
Cohen et al. 
1985 [47] 
13/20 PGE2 Multiple pro-
inflammatory and 
Protein PTS† RIA y 
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immunomodulatory 
effects 
  PGF2α Multiple pro-
inflammatory and 
immunomodulatory 
effects 
Protein PTS† RIA y 
Cootauco et al. 
1993* [73] 
5/8 α-2M Neutralization of 
proteinases 
Protein  IHC n/a 
Dong et al. 1999 
[83] 
9/11 6-K-
PGF1α  
Vasodilators; inhibits the 
aggregation of blood 
platelets; involved in 
inflammation 
Protein PTS RIA y 
 
  TXB2  Involved in platelet 
aggregation, 
vasoconstriction and 
reproductive functions 
Protein PTS RIA y 
Khabbaz et al. 
2001 [84] 
15/5 Endotoxin
s 
Induces strong immune 
response 
Protein 
activity 
PTS LAL y 
Nakanishi et al. 
2001* [85] 
10/5 COX-2 Prostaglandin synthesis Protein  IHC n/a 
Guven et al. 
2007* [86] 
12/12   Protein FPT IHC n/a 
Awawdeh et al. 
2002 [87] 
46/20 Substance 
P 
Vasoactive mediator, 
immune mediator 
Protein PTS RIA y 
 
Caviedes-
Bucheli et al. 
2006 [88] 
6/6   Protein PTS RIA y 
Awawdeh et al. 
2002 [87] 
46/20 Neurokinin 
A 
Generates three 
different 
preprotachykinins 
Protein PTS RIA y 
Caviedes-
Bucheli et al. 
2006 [88] 
6/6   Protein PTS RIA y 
Awawdeh et al. 
2002 [87] 
46/20 CGRP Vasodilation and 
increased microvascular 
permeability 
Protein PTS RIA y 
Caviedes-
Bucheli et al. 
2004 [89] 
5/5   Protein Pulp 
cells in 
suspensi
on 
Flow 
cytometry 
y 
Caviedes-
Bucheli et al. 
2005 [90] 
6/4 
 
  Protein PTS RIA y 
Caviedes-
Bucheli et al. 
2006 [88] 
6/6   Protein PTS RIA y 
Caviedes-
Bucheli et al. 
2006 [88] 
6/6 Neuro-
peptide Y 
Potent vasoconstrictor, 
parasympathetic 
nervous system 
Protein PTS RIA y 
   VIP Vasodilator, 
parasympathetic 
nervous system 
Protein PTS RIA n 
da Silva et al. 
2008* [78] 
6/6 NOD2 Involved in host 
response against 
bacteria 
mRNA PTS RT-PCR y 
Keller et al. 2009 
[56] 
5/5   mRNA PTS RT-PCR y 
Growth Factors 
Artese et al. 
2002* [91]  
25/25 VEGF Stimulates 
vasculogenesis and 
angiogenesis 
Protein FPT IHC n/a 
Guven et al. 
2007* [86]* 
12/12   Protein FPT IHC n/a 
Abd-Elmeguid et 
al. 2013* [49] 
12/30   Protein PTS Multiplex 
assay 
n 
Abd-Elmeguid et 
al. 2013* [49] 
12/30 FGF  Involved in 
angiogenesis, wound 
healing, embryonic 
Protein PTS Multiplex 
assay 
n 
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development and 
various endocrine 
signaling pathways 
Antimicrobial peptides 
Paris et al. 2009 
[50] 
10/7 hBD-1 Activates the innate and 
adaptive immune 
system. Chemotactic for 
monocytes, T-
lymphocytes, dendritic 
cells and mast cells 
mRNA PTS RT-PCR y 
  hBD-2  mRNA PTS RT-PCR n 
  hBD-3  mRNA PTS RT-PCR n 
  hBD-4  mRNA PTS RT-PCR y 
Others 
Caviedes-
Bucheli et al. 
2007 [92] 
5/5 Substance 
P receptor 
Vasoactive mediator, 
immune mediator 
Protein PTS RIA y 
Caviedes-
Bucheli, Moreno, 
et al. 2008 [93] 
13/13 AAMø 
CD163+ 
expressing 
CGRPr 
Alternatively activated 
polarized 
monocyte/macrophage; 
different phenotype 
compared to the 
classical ones. Then 
expressing CD163+ 
Protein Pulp 
cells in 
suspensi
on 
Flow 
cytometry 
See text 
Suwanchai et al. 
2012 [66] 
7/18 NaV 1.8 Initiation and 
propagation of action 
potentials; involved in 
pain perception 
Protein PTS Western blot y 
  NaV 1.9 Initiation and 
propagation of action 
potentials; involved in 
pain perception 
Protein PTS Western blot y 
Zhong et al. 
2012 [94] 
18/12 miRNAs Regulators of post-
transcriptional gene 
expression in biological 
processes like 
inflammation, immune 
response, and 
osteoclastic bone 
resorption 
mRNA PTS Microarray See text  
Dong et al. 
2013* [95]* 
21/12 EphA7 Involved in embryonic 
development, 
angiogenesis, 
tumorigenesis, 
inflammation & pain 
Protein FPT IHC y 
    mRNA PTS RT-PCR y 
 
* Pulpal inflammation confirmed histologically; † Substrate pooled before analysis; y: Yes; n: 
No; n/a: Not applicable. 
Analytes were mostly either pulp tissue supernatant (PTS) or fixed pulp tissue (FPT). One study 
used pulp cells in suspension, another one pulpal fluid. Analytical methods used included reverse 
transcription polymerase chain reaction (RT-PCR), multiplex assay, microarray, Western Blot, 
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radioimmunoassay (RIA), immunohistochemistry (IHC), enzyme-linked immunosorbent assay 
(ELISA), zymography, flow cytometry, limulus amoebocyte assay (LAL), and specific enzyme 
assays. 
 
Table 2. Studies assessing other substrates than pulp tissue for the presence of a 
biomarker. 
 
Reference  
n in group 
(irreversibly 
inflamed/ 
non- 
inflamed) Biomarker  Function Target Analyte Analysis 
 
Significant 
difference 
between 
groups 
Cytokines 
Nakanishi et al. 
1995 [44] 
27/9 IL-1α Regulates immune and 
inflammatory reactions; 
stimulates bone 
resorption 
Protein PB ELISA n 
  IL-1β Regulates immune and 
inflammatory reactions; 
stimulates bone 
resorption 
Protein PB ELISA n 
Elsalhy et al. 
2013 [45] 
43/25 IL-2 Regulates the activities 
of leukocytes 
Protein PB ELISA n 
Nakanishi et al. 
1995 [44] 
27/9 IL-6 Regulator of T- and B-
cell growth, acute phase 
protein production 
Protein PB ELISA Not detected 
Elsalhy et al. 
2013 [45] 
43/25   Protein PB ELISA y 
Karapanou et al. 
2008 [1] 
17/17 IL-8 Recruitment and 
activation of neutrophils 
Protein GCF ELISA y 
Elsalhy et al. 
2013 [45] 
43/25   Protein PB ELISA y 
Elsalhy et al. 
2013 [45] 
43/25 IL-10 Multiple effects in 
immunoregulation and 
inflammation; anti-
inflammatory   
Protein PB ELISA y 
Nakanishi et al. 
1995 [44] 
27/9 TNF-α Delays neutrophil 
apoptosis 
Protein PB ELISA n 
Karapanou et al. 
2008 [1] 
25/25   Protein GCF ELISA Not detected 
Elsalhy et al. 
2013 [45] 
43/25   Protein PB ELISA y 
Elsalhy et al. 
2013 [45] 
43/25 IFN-γ Cytokine that is critical 
for innate and adaptive 
immunity 
Protein PB ELISA y 
Proteases and other enzymes 
Zehnder et al. 
2011 [33] 
16/12 MMP-9 Hydrolysis of 
intercellular matrix; 
regulatory factor for 
neutrophil migration 
across basement 
membranes 
Protein 
activity 
Dentinal 
fluid 
Enzyme 
assay 
y 
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Nakanishi et al. 
1995 [44] 
27/9 Elastase Cleavage of elastin, 
collagen, proteoglycans 
Protein PB ELISA y 
       
Vasoactive agents 
Lepinski et al. 
2000 [41] 
11/10 Bradykinin Vasodilator involved in 
pain and inflammation 
mechanisms 
Protein Extracell
ular 
pulpal 
fluid 
RIA y 
Bowles et al. 
2003 [42] 
16/8   Protein Extracell
ular 
pulpal 
fluid 
RIA y 
Others 
Nakanishi et al. 
1995 [44] 
27/9 IgG Antigen neutralization Protein PB ELISA y 
Nakanishi et al. 
1995 [44] 
27/9 IgA Antigen neutralization Protein PB ELISA y 
Nakanishi et al. 
1995 [44] 
27/9 IgM Antigen neutralization Protein PB ELISA y 
Nakanishi et al. 
1995 [44] 
27/9 PGE2 Multiple pro-
inflammatory and 
immunomodulatory 
effects 
Protein PB ELISA y 
Evcil et al. 2006 
[46] 
16/16 Serum NO Cellular signaling 
molecule involved in 
many physiological and 
pathological processes 
Protein 
activity 
Peripher
al blood 
serum 
 
Serum 
assay 
n 
 
y: Yes; n: No.  
Analytes were mostly either pulpal blood (PB) or gingival crevicular fluid (GCF). Extracellular 
pulpal fluid and peripheral serum were used in one study each. Analytical methods used included 
radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and specific serum or 
enzyme assays. 
 
 
Discussion 
 
The results point to a response in pulpitis by immunocompetent tissues that ultimately results in 
the release of mediators, which in turn trigger a series of inflammatory events and an attempt to 
initiate repair. Collectively, the data presented here demonstrate the involvement of various 
TLR-induced chemotactic molecules (i.e. IL-8, CXCL-10, MIP family, GRO, MCP family, 
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RANTES, Eotaxin, IP10, and others). 
TLRs have been shown to confer immunocompetence to the dental pulp [56]. They are expressed 
by both immune and non-immune cells in the pulp including neurons, fibroblasts, endothelial 
cells, epithelial cells and others, which recognize viral and microbial structures as well as self 
molecules (such as single stranded RNAs) that may accumulate in non-physiologic amounts or 
sites during inflammation [96-100].  
Under normal conditions, very few immune cells are present in the dental pulp [101]. In the 
presence of infection (i.e. caries), immune cells are recruited to the pulp even in the absence of 
direct bacterial contact on the pulp tissue itself. The permeability of dentin to soluble bacterial 
products allows pulpal response to occur prior to carious pulpal exposure. These soluble bacterial 
products, along with components of the complement system and products of the lipoxygenase 
pathway of arachidonic acid metabolism are chemotactic for leukocytes [102].  
The exponential increase in the number of infiltrating leukocytes brings with it a corresponding 
increase in lysosomal enzymes that cause tissue damage. Proteases like elastase and MMPs 
(Table 1 and 2) cleave elastin and proteoglycans that destroy the pulp tissue resulting in 
irreversible damage [33, 58, 63]. Furthermore, the accompanying spike in inflammatory 
mediators like PGE2, cAMP, COX-2, CGRP, neurokinins and others stimulate vasodilation and 
microvascular permeability by binding into their respective receptors (i.e. EP2/3 receptor for 
PGE2) and induce cytoskeletal rearrangement or contraction of vascular smooth muscle [103].  
Equally as important is the action of neuropeptides (e.g. substance P, calcitonin-gene related 
peptide) (Table 1). These neuropeptides typically reside in endings of afferent nerve close to 
blood vessels but also associated with macrophages and odontoblasts [104]. As a response to 
stimuli, afferent nerve sprouting has been demonstrated, and with it an increase in neuropeptide 
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concentration [105], which can cause spontaneous pain, allodynia or hyperalgesia in teeth with 
pulpitis.  
Simultaneous to the destructive effects of leukocytic infiltration is the capability of these cells to 
induce repair through the release of VEGF, TGF-B, GM-CSF and others (Table 1 and 2) that 
induce alterations of the local extracellular matrix, promote induction of endothelial cells to 
migrate or proliferate, and inhibition of vascular growth with formation of differentiated 
capillaries [106]. The increased expression in inflamed pulp of toll-mediated human beta-
defensins (hBD) [50] that play an important role in the innate host defense against bacterial 
invasion, contribute to promotion of adaptive immune responses, and show chemotactic 
activities further underscore the dynamic range of response of the dental pulp during 
inflammation. In addition, it can also be appreciated that during pulpal inflammation, the anti-
inflammatory effects of various mediators such as tissue inhibitors of matrix proteinases 
(TIMPs), siRNA [94, 107] and others also come into play. 
As a direct result of the release of inflammatory biomarkers, pulpal responses include classical 
signs of inflammation specifically a vascular response, along with changes in mediator profiles 
and cellular constituents. The transition from reversible to irreversible pulpitis has been broadly 
characterized by a migration of dendritic cells towards odontoblasts and accumulation of 
immune cells [108]. However, a more detailed analysis such in the majority of studies included 
in this paper evaluating biomarkers of pulpal inflammation demonstrates (statistical) significant 
differences between a clinically diagnosed healthy or irreversibly inflamed pulp at the molecular 
level.  
Moreover, the analytes were obtained via different approaches both from the pulp directly as 
well as indirectly from tissue fluid. Figure 4 illustrates the potential sampling sites for molecular 
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pulpal diagnostics [34]. While having the benefit to show a direct picture of intrapulpal 
conditions using pulpal blood [26] or whole pulp tissue requires access to the pulp space and is 
therefore not applicable as a chairside screening tool. Conversely, indirect methods such as 
dentin fluid collection or assessment of mediators in GCF can be performed clinical in a less 
invasive way. Dentin fluid is the extracellular fluid that is contained within dentinal tubules 
[109]; its composition includes inflammatory mediators and vasoactive compounds associated 
with inflammation. While initial evidence suggested that these mediators can be assayed [33] 
problems exist with protein yield [27] and the need to remove the existing restoration or in other 
cases to prepare an initial cavity deep in dentin. 
 
Fig 4. Actual and potential sampling sites to assay pulpal mediators. 
 
GCF was used to sample mediators in one study included here (Table 2) [1]. This fluid is an 
exudate that from the gingival crevice and it contains several host factors including antibodies, 
bacterial antigens, proteins, and cytokines [110, 111]. GCF analyses may be promising due to the 
ease of application. Moreover, it may be possible to assess the dynamics of apical periodontitis 
using GCF [34]. However, the major drawback in the evaluation of host mediators in GCF is that 
tissue inflammation, independent of its cause, is a non-specific process of innate immunity [112] 
and this makes it difficult to distinguish on a molecular level between a marginal and apical 
periodontal inflammation. When sampling from the GCF for pulpal diagnostics, this potential 
drawback could be overcome by (i) creating healthy periodontal conditions, (ii) averaging out 
several sites on one or multiple teeth, (iii) combining clinical and radiographic observations, or 
(iv) defining a specific pattern of metabolites relevant to the pulp and not the periodontium, or 
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possibly by other as yet unidentified means. Furthermore, the detection of mediators of pulpitis 
in GCF is impacted by the need for these compounds to reach the periodontal ligament and 
ultimately the gingival crevice in sufficient concentrations. Indeed, the notion that mediators will 
diffuse from the pulp via dentinal tubules or accessory canals to the periodontal ligament has 
been called into question [87]. Periapical fluid samples, while requiring a direct access to the 
apical site, are of interest to determine the level of systemic inflammation [28]. 
Discovering an improved method to determine the present inflammatory condition of the pulp 
could be of great value: on the one hand, pulp necrosis is one of the most frequent complications 
after coronal restoration of assumed non-inflamed (vital) teeth, on the other performing a full 
pulpectomy on teeth that could have been kept vital (at least in part) suggests that overtreatment 
may occur in many cases [113]. Endodontic diagnosis should therefore focus on either the extent 
of the microbial infection or the inflammatory reaction of the host tissue; however, current 
methods do neither [14, 23, 34].  
Keeping a pulp vital offers distinct advantages compared to root canal treatment: the protective 
immune capacity of the pulp remains preserved and the remaining tooth structure gets not 
unnecessarily weakened by access cavity preparation and root canal enlargement. Unfortunately, 
the only available long-term outcome studies on direct pulp capping procedures (i.e. direct pulpal 
interventions), which attempt to maintain pulpal vitality, show unsatisfactory success rates as 
low as 20% after ten years [114]. The development of biocompatible materials facilitates a 
wound closure free of inflammation after pulpal capping procedures or partial pulpotomy [108]. 
However, the likelihood of a pulp to survive such procedures remains questionable using current 
schemes for assessment of pulpal inflammation. 
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One limitation of this systematic review is that merely 2 out of 57 studies [33, 45] were 
specifically designed to investigate potential biomarkers in the context of pulpal diagnostics. 
Most of the studies analyzed here merely target the presence of molecules and their function in 
pulpal inflammation. Nevertheless, based on the current state of knowledge this review provides 
an overview on molecules that are present and measurable during pulpal inflammation and 
therefore potentially can serve as a biomarker for pulpal inflammation. This may provide 
impulses for further research. This research needs to explore patient (age, gender, systemic 
condition) and infection related factors (varying composition of the microbiological infection). 
Clinical investigations should be conducted that are specifically designed to confirm the results 
collected from the research collected here. More specifically mediator profiles should be 
assessed in defined clinical scenarios. In addition, the assays methodology should be tested for 
their applicability with the possible substrates. The ultimate goal should then be to develop an 
inexpensive chairside test for non-invasive molecular pulp diagnostics. In fact, such a chair-side 
assay, based on the immunochromatographic detection of MMP-8 specific antibodies, is already 
commercial available to diagnose periodontal inflammation [115]. For endodontic procedures of 
the future, such as partial pulpotomies and pulp regeneration, a comparable test will be of 
significant value. 
Indeed, various biomarkers that are produced by cellular components of the dental pulp can 
provide a snapshot of the biological mechanisms that propel this immunocompetent tissue 
towards healing or necrosis. The imbalance between tissue destructive molecules like proteases 
and tissue inductive molecules like VEGF may serve as a diagnostic or prognostic tool for 
endodontic intervention. The challenge remains on developing a method to make these 
biomarkers readily measureable in a clinical setting.  
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Conclusions 
In the included studies, irreversible pulpitis was associated with different expression of various 
biomarkers compared to non-inflamed controls. These biomarkers were significantly expressed 
not only in pulp tissue, but also in gingival crevicular fluid that can be collected non-invasively 
and in dentin fluid that can be analyzed without extirpating the pulpal tissue. This may be used to 
accurately differentiate diseased from healthy pulp tissue. The main current challenges in the 
clinical application of biomarkers lie in the identification of biomarkers or biomarker subsets that 
reliably correlate with pulpal inflammation, the improvement of sample collection (substrate and 
protein yields), and their analysis (interference of the biomarkers with inflammation of other than 
pulpal origin). If these hurdles can be overcome, a more accurate pulpal diagnosis and more 
predictable vital pulp treatment regime may create better clinical outcomes.  
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outcomes, and study design (PICOS).  
p. 7 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
p. 7-9 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-­‐up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
p. 7, 8; S3 
Table  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
p. 7, 8; S3 
Table 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
S2 Table 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-­‐analysis).  
p. 8, 9 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
p. 8, 9, 10 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
p. 10 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
p. 9, 10 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  p. 10 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-­‐analysis.  
n/a 
PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
n/a 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-­‐specified.  
n/a 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
p. 8, 9; Fig 
2, S4 Table 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Table 1 & 2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Fig 3,  
S5 Table 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 1 & 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  n/a 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  n/a 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  n/a 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
p. 21, 22, 27 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
p. 26 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  p. 26, 27 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
Provided 
during 
manuscript 
submission 
process 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-­‐statement.org.  
PRISMA 2009 Checklist 
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S2 Table  Example of search strategy (here in Medline database) employed for  
  this literature review 
 
Number Search history Results 
1 (Exp Pulpitis/ OR ((acute or irreversible or painful) adj3 pulpitis).tw. 
OR (pulp* adj3 inflam*).tw.)  
2884 
2 dentinal fluid/ or gingival crevicular fluid/ OR  
exp metalloendopeptidases/ or exp matrix metalloproteinases/ OR 
exp Biological Markers/an, ch, du, me OR exp inflammation 
mediators/ or exp "intercellular signaling peptides and proteins"/ 
OR "Osteoprotegerin"/ OR exp receptors, cytokine/ or 
osteoprotegerin/ OR *"Intracellular Signaling Peptides and 
Proteins"/ OR *"Lymphocytes"/ OR exp "Intracellular Signaling 
Peptides and Proteins"/ OR exp Antimicrobial Cationic Peptides/  
1724182 
3 ((pulp* or dentin*) adj3 (tissue or fluid or liquor or supernatant)).tw. 2423 
4 (gingival adj3 fluid).tw. 2275 
5 biomarker.tw 50450 
6 ((biological or diagnostic or inflammat*) adj3 (marker or 
mediator)).tw. 
17323 
7 (cytokin* or interferon* or tgf* or tnf* or interleukin* or 
metalloproteinase* or elastase* or lactoferrin or 
osteoprotegerin).tw. 
580865 
8 (antimicrobial adj3 peptides).tw. 6692 
9 OR/2-7 1909267 
10 1 AND 9 563 
11 10 NOT (exp Cells, Cultured/ OR (animals not humans).sh.) 347 
 
 
 
 
S3 Table  Hits from the literature search obtained with the different databases 
Database Inception of 
database 
Hits After duplicate removal 
Medline 
 
1984 347 
 
343 
 
Embase 
 
1974 334 88 
Cochrane 
 
1995 17 9 
ISI Web of 
Science 
 
1899 430 237 
Biosis 
 
1980 181 64 
Scopus 
 
Pooled hits 
 
1996 420 
 
1729 
106 
 
847 
 
S4 Table  Studies excluded from the final analysis 
 
 
Studies that did not use human teeth for analysis: 
 
 
Mutoh et al. 2007 [1] 
 
 
Studies on cell cultures only: 
 
 
Hahn and Falkler 1992 [2], Casasco et al. 1994 [3], Barkhordar et al. 2002 [4], Lu et 
al. 2002 [5], Huang et al. 2006 [6], Huang et al. 2008 [7], Killough et al. 2009 
[8], Lin et al. 2009 [9], Alongi et al. 2010 [10], Sattari et al. 2010 [11], Wang et 
al. 2010 [12], Hui et al. 2014 [13] 
 
 
 
No potential biomarker was investigated or the study was off topic: 
 
 
Maita and Horiuchi 1990 [14], Knutsson et al. 1994 [15], Tasman et al. 1999 [16], 
Wahlgren et al. 2002 [17], Rowland et al. 2007 [18], Avellan et al. 2008 [19], 
Rodriguez and Calero 2008 [20], Sattari et al. 2009 [21], Beneng et al. 2010 
[22], Abd-Elmeguid et al. 2012 [23], Pereira et al. 2012 [24], Ruparel et al. 
2013 [25] 
 
 
 
No clear distinction between reversible, irreversible or necrotic pulp: 
 
 
Pulver et al. 1977 [26], Speer et al. 1977 [27], Messelt et al. 1978 [28], Viti et al. 1985 
[29], Gregoire and Terrie 1990 [30], Davis et al. 1991 [31], Grossi et al. 1991 
[32], McClanahan et al. 1991 [33], Proctor et al. 1991 [34], Rauschenberger et 
al. 1991 [35], Skaljac-Staudt et al. 1991 [36], Rauschenberger, McClanahan et 
al. 1994 [37], Goodis and Saeki 1997 [38], Sawa et al. 1998 [39], Barkhordar 
et al. 1999 [40], Guo et al. 2000 [41], Hahn et al. 2000 [42], Ohnishi et al. 2000 
[43], Rodd and Boissonade 2000 [44], Kuntz et al. 2001 [45], Nup et al. 2001 
[46], Jukic et al. 2002 [47], Shin et al. 2002 [48], Pimenta et al. 2003 [49], 
McLachlan et al. 2004 [50], Paakkonen et al. 2005 [51], Dourou et al. 2006 
[52], El Karim et al. 2006, [53] Rodd and Boissonade 2006 [54], El Karim et al. 
2008 [55], Wang et al. 2008 [56], Warren et al. 2008 [57], Zhang et al. 2008 
[58], Vavilova et al. 2009 [59], Cardoso et al. 2010 [60], Korkmaz et al. 2011 
[61], Lee et al. 2011 [62], Zhao et al. 2011 [63], Evrosimovska et al. 2012 [64], 
Petrini et al. 2012 [65], Martin-Gonzalez et al. 2013 [66] 
 
 
 
 
Studies rather on histologic features or presence of cells, bacteria or viruses than on 
quantification of a biomarker: 
 
 
Pekovic and Fillery 1984 [67], Jacoby et al. 1991 [68], Casasco et al. 1992 [69], Izumi 
et al. 1995 [70], Wu and Wen 1995 [71], Kobayashi et al. 1996 [72], Marchetti 
1996 [73], Zerosi et al. 1999 [74], Mousavi et al. 2006 [75], Pisterna and 
Siragusa 2007 [76], Manolea et al. 2008 [77], Rosaline et al. 2009 [78], Bruno 
et al. 2010 [79], Marigo et al. 2010 [80] 
 
 
 
 
Review articles, editorials, comments, abstract only or case reports: 
 
 
 Ahlberg 1978 [81], Zelante et al. 1980 [82], D'Souza and Lachman 1989 [83], 
Jackson et al. 1992 [84], Rauschenberger and Cootauco 1993 [85], Goodis et 
al. 1994 [86], Matsuo et al. 1994 [87], Rauschenberger, Cootauco et al. 1994 
[88], Taniishii et al. 1994 [89], Maclean et al. 1995 [90], Potente et al. 1998 
[91], Huang et al. 2000 [92], Lopez-Costa et al. 2000 [93], Chidchuangchai et 
al. 2003 [94], Higuera 2012 [95], Martin Gonzalez et al. 2012 [96], Martin 
Jimenez et al. 2012 [97], Sanchez Dominguez 2012 [98], Segura Egea et al. 
2012 [99] 
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